Drugs Made In America Acquisition Corp. (DMAA)

DMAA Biotech / Pharma

BiotechSign Signal Grade

F
Signal Grade
10.8/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
65
Clinical Activity
0
Short Interest
10

Pipeline Overview

Therapeutic Focus
Biotech / Pharmasrc

Clinical Trial Activity

0
Clinical Trials
(ClinicalTrials.gov aggregate)
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
0.5 months
Cash Runway Estimate
65/100
Dilution Score
40Warrant Risk
40Convertible Risk
36Offering Ability

Dilution score: 65/100 (HIGH), 0.5 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

0.00%
Float Shorted
1.3
Days to Cover
LOW
Squeeze Risk
+16.5%
SI Change
INCREASING
Trend
92,523
Shares Short

Short interest: ?% of float, squeeze risk: LOW

FINRA short sale data. FINRA short interest

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Drugs Made In America Acquisition Corp..

Full DMAA Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.